PAG
SRPT icon

Private Advisor Group’s Sarepta Therapeutics SRPT Stock Holding History

Private Advisor Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-190
Closed -$30K – 3171
2020
Q2 		$30K Buy
+190
New +$25.9K ﹤0.01% 2360
2019
Q3 		– Sell
-1,680
Closed -$255K – 1778
2019
Q2 		$255K Buy
+1,680
New +$204K ﹤0.01% 1373

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Private Advisor Group's SRPT Position: Q3 2020 in Review

Private Advisor Group sold out of Sarepta Therapeutics (SRPT) in Q3 2020, closing a stake of 190 shares — an estimated $30K sold.

Private Advisor Group first reported a position in SRPT in Q2 2019 and held it in 2 quarters. The position peaked at $255K in Q2 2019. 403 funds tracked by Wall St. Rank hold SRPT as of Q3 2020.

  • Private Advisor Group reported no remaining Sarepta Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Private Advisor Group sold 190 Sarepta Therapeutics shares in Q3 2020, an estimated $30K.
  • Private Advisor Group first reported a position in Sarepta Therapeutics in Q2 2019 and held it in 2 quarters.
  • Private Advisor Group's Sarepta Therapeutics position peaked at $255K in Q2 2019.
  • 403 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.